You are here

vupanorsen

Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market

Fierce Biotech

Mon, 01/31/22 - 10:47 am

Ionis Pharmaceuticals

Pfizer-licensed Cardiovascular Drug Reduces Triglycerides in Phase II

BioSpace

Fri, 11/26/21 - 08:49 pm

Akcea Therapeutics

clinical trials

Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet

Fierce Biotech

Wed, 11/24/21 - 10:15 am

clinical trials

Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen

Pharmaceutical Business Review

Wed, 11/4/20 - 10:13 am

Ionis Pharmaceuticals

Akcea Therapeutics

clinical trials